Back to search

France· FR:63945150

FOMEPIZOLE AP-HP 5 mg/mL, solution à diluer pour perfusion

A fomepizole product containing sulfate de fomépizole, registered in France by ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS - AP-HP. The same ATC class is registered in 14 of our 19 countries.

ATC V03AB34

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedFOMEPIZOLE AP-HP 5 mg/mL, solution à …ATCV03AB34REGISTER NO.FR:63945150PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Fomepizole is registered in 14 of 19 countries.

Countries holding a registration under ATC V03AB34 (fomepizole), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 7 of them publish a price we can compare per daily dose

Fomepizole · ATC V03AB34

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
SULFATE DE FOMÉPIZOLE
Manufacturer
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS - AP-HP
Country
France (FR)
ATC code
V03AB34
ATC class
Fomepizole
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400956202331
    5 ampoule(s) en verre de 20 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

4 interactions on record for fomepizole.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Fomepizole · interactions on record

4 records

  • 4 severe

Most severe, free to view

  • EthanolB05XX04severe
  • EthanolV03AB16severe
  • EthanolV03AZ01severe
  • EthanolV07AB03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Fomepizole in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fomepizole products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • United Kingdom (Northern Ireland) · Fomepizole Waymade

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/20b0814f-8eab-465c-be8a-7d42ac3dc19a
GET /v1/drugs/20b0814f-8eab-465c-be8a-7d42ac3dc19a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "63945150",
  "date_amm": "1999-05-06",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "SULFATE DE FOMÉPIZOLE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about fomepizole.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.